

Lung Cancer: where we are? Fourth Edition

07.04.2026

IRST IRCCS “Dino Amadori” - Meldola

Scientific Chairs: Dott. Delmonte, Dott. Normanno, Dott. Parisi, Prof. Crinò

8.30 Registration

9.00 Introduction from the Scientific and General Directors and from Scientific Chairs

2 SESSION

Oncogene addicted, advanced diseases

Chairs: Dott. Paola Ulivi, Prof. Lucio Crinò

11.30 Sex and gender in lung cancer: which role? – Prof. Rossana Berardi, Ancona

11.45 Liquid biopsy in lung cancer: where are we? – Prof. Umberto Malapelle, Napoli

12.00 EGFR mutants: different therapies for different tumors – Dott. Antonio Passaro, Milan

12.15 KRAS oncogene addicted tumors - Prof. Diego Cortinovis, Milan

12.30 Rare oncogene addicted tumors (ALK, ROS1, BRAF, RET, MET, NTRK, HER2) – Dott. Kalliopi Andrikou, IRST

12.45 Antibody Conjugates in lung cancer - Dott. Francesca Fusco, Milano

13.00 Discussion

13.15 Light Lunch

4 SESSION

Rare Thoracic Cancers

Chairs: Dott. Davide Tassinari, Dott. Angelo Delmonte

15.45 Tumors of the Thymus: future perspectives – Dott. Tommaso Martino De Pas, Bergamo

16.00 Small Cell Lung Cancer: state of the art for local and extended disease - Dott. Alberto

Verlicchi, IRST

16.15 Small Cell Lung Cancer: new therapeutic options – Dott. Federica Bertolini, Modena

16.30 Pleural mesothelioma: a new landscape? – Prof. Luana Calabrò, Ferrara

16.45 Discussion

17.00 Conclusions

RATIONALE

Lung cancer is the first cause of death for tumors worldwide.

However several improvements have been obtained mainly due to the increased biologic knowledge.

In fact today with the term lung cancer we consider a group of several diseases, distinguished according to histology and molecular features.

These aspects are fundamental in order to define the most active therapeutic strategies. This landscape is rapidly evolving and every year new data are available.

So far it is particularly important to have the possibility to discuss the new data together with outstanding experts in order to improve the knowledge for a better cure for patients.

Acronimi:

NSCLC - carcinoma polmonare non a piccole cellule

EGFR - Estimated Glomerular Filtration Rate

KRAS - Kirsten Rat Sarcoma Viral Oncogene Homolog

ALK - Anaplastic Lymphoma Kinase

ROS1 - proto-oncogene 1, recettore tirosin-chinasi

BRAF - B-Raf proto-oncogene, serine/threonine kinase

RET - REarranged during Transfection

MET - Metabolic Equivalent of Task

NTRK - Neurotrophic Tyrosine Receptor Kinase

HER2 - Human Epidermal Growth Factor Receptor 2